Did the 31 biotechs who pulled IPOs since 2003 destroy value? By and large, no—thanks to a growing variety of financing and exit options. Roger Longman Like divorce, withdrawing an initial public offe
Mid-sized Schwarz is aggressively pursuing in-licensing to grow its international infrastructure. Will investors see the strategy's value? by Deborah Erickson In 1985, Schwarz Pharma AG of Monheim,